Compounds > tretazicar
Page last updated: 2024-08-26

tretazicar and mitomycin

tretazicar has been researched along with mitomycin in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (50.00)18.2507
2000's3 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sugget, N; Walton, MI; Workman, P1
Riley, RJ; Workman, P1
Melo, T; Misra, V; Rauth, AM1
Ackerley, DF; Barak, Y; Contag, CH; Lynch, SV; Matin, A; Thorne, SH1
Celli, CM; Jaiswal, AK; Knox, R; Tran, N1
Boddy, AV; Jamieson, D; Knox, RJ; Tung, AT1

Reviews

1 review(s) available for tretazicar and mitomycin

ArticleYear
DT-diaphorase and cancer chemotherapy.
    Biochemical pharmacology, 1992, Apr-15, Volume: 43, Issue:8

    Topics: Animals; Antineoplastic Agents; Aziridines; Benzoquinones; Dihydrolipoamide Dehydrogenase; Drug Design; Enzyme Induction; Gene Expression Regulation, Enzymologic; Humans; Indolequinones; Indoles; Mitomycin; Neoplasms; Precancerous Conditions; Tirapazamine; Triazines

1992

Other Studies

5 other study(ies) available for tretazicar and mitomycin

ArticleYear
The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins.
    International journal of radiation oncology, biology, physics, 1992, Volume: 22, Issue:4

    Topics: Animals; Antineoplastic Agents; Aziridines; Carcinoma 256, Walker; Cell Hypoxia; Colonic Neoplasms; Humans; In Vitro Techniques; Indolequinones; Indoles; Mitomycin; NAD(P)H Dehydrogenase (Quinone); Oxidation-Reduction; Prodrugs; Rats; Tirapazamine; Triazines

1992
Bioreductive therapies: an overview of drugs and their mechanisms of action.
    International journal of radiation oncology, biology, physics, 1998, Nov-01, Volume: 42, Issue:4

    Topics: Animals; Antineoplastic Agents; Aziridines; Cell Hypoxia; DNA, Neoplasm; Forecasting; Humans; Indolequinones; Indoles; Misonidazole; Mitomycin; Nitrofurans; Nitroimidazoles; Oxidation-Reduction; Prodrugs; Radiation-Sensitizing Agents; Tirapazamine; Triazines

1998
New enzyme for reductive cancer chemotherapy, YieF, and its improvement by directed evolution.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:1

    Topics: Antineoplastic Agents; Aziridines; Drug Delivery Systems; Escherichia coli Proteins; Evolution, Molecular; HeLa Cells; Humans; Mitomycin; Neoplasms; Oxidoreductases; Prodrugs; Salmonella typhimurium; Sequence Analysis, Protein

2006
NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs.
    Biochemical pharmacology, 2006, Jul-28, Volume: 72, Issue:3

    Topics: Animals; Antineoplastic Agents; Aziridines; Benzopyrenes; Biotransformation; Cell Survival; Cells, Cultured; CHO Cells; Cricetinae; Cricetulus; Cross-Linking Reagents; DNA, Complementary; Dose-Response Relationship, Drug; Hydroquinones; Indolequinones; Keratinocytes; Mice; Mice, Knockout; Mitomycin; Mitomycins; Quinone Reductases; Quinones; Transfection; Vitamin K 3

2006
Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor.
    British journal of cancer, 2006, Nov-06, Volume: 95, Issue:9

    Topics: Alkylating Agents; Animals; Aziridines; Catalysis; Cell Line; Comet Assay; Electron Transport; Humans; Mitomycin; NAD; NAD(P)H Dehydrogenase (Quinone); Oxidation-Reduction; Quercetin; Quinone Reductases; Recombinant Proteins; Transfection

2006